TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway

被引:28
|
作者
Liu, Weiguang [1 ]
Chen, Guanglei [2 ]
Sun, Lisha [2 ]
Zhang, Yue [3 ]
Han, Jianjun [1 ]
Dai, Yuna [1 ]
He, Jianchao [1 ]
Shi, Sufang [1 ]
Chen, Bo [4 ]
机构
[1] Hebei Univ Engn, Affiliated Hosp, Dept Breast Surg, Handan, Peoples R China
[2] China Med Univ, Shengjing Hosp, Dept Breast Surg, Shenyang, Liaoning, Peoples R China
[3] Dalian Med Univ, Dept Physiol, Dalian, Peoples R China
[4] China Med Univ, Dept Breast Surg, Hosp 1, Shenyang, Liaoning, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
中国国家自然科学基金;
关键词
triple negative breast cancer (TNBC); TUFT1; Rac1; metastasis; stemness; chemoresistance; BETA-CATENIN; COLORECTAL-CANCER; RHO-GTPASES; PANCREATIC-CANCER; CELL PHENOTYPES; RAC1; ACTIVATION; SIGNALS; NANOG; SOX2; PROLIFERATION;
D O I
10.3389/fonc.2019.00617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Triple negative breast cancer (TNBC) is a subtype of breast cancer with stronger invasion and metastasis, but its specific mechanism of action is still unclear. Tuft1 plays an important regulatory role in the survival of breast cancer cells; however, its role in regulating TNBC metastatic potential has not been well-characterized. Our aim was therefore to systematically study the mechanism of TUFT1 in the metastasis, stemness, and chemoresistance of TNBC and provide new predictors and targets for BC treatment. Methods: We used western blotting and IHC to measure TUFT1 and Rac1-GTP expression levels in both human BC samples and cell lines. A combination of shRNA, migration/invasion assays, sphere formation assay, apoptosis assays, nude mouse xenograft tumor model, and GTP activity assays was used for further mechanistic studies. Results: We demonstrated that silencing TUFT1 in TNBC cells significantly inhibited cell metastasis and stemness in vitro. A nude mouse xenograft tumor model revealed that TUFT1 knockdown greatly decreased spontaneous lung metastasis of TNBC tumors. Mechanism studies showed that TUFT1 promoted tumor cell metastasis and stemness by up-regulating the Rac1/beta-catenin pathway. Moreover, mechanistic studies indicated that the lack of TUFT1 expression in TNBC cells conferred more sensitive to chemotherapy and increased cell apoptosis via down-regulating the Rac1/beta-catenin signaling pathway. Further, TUFT1 expression positively correlated with Rac1-GTP in TNBC samples, and co-expression of TUFT1 and Rac1-GTP predicted poor prognosis in TNBC patients who treated with chemotherapy. Conclusion: Our findings suggest that TUFT1/Rac1/beta-catenin pathway may provide a potential target for more effective treatment of TNBC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] RAC1 GTP-ase signals wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers
    De, Pradip
    Carlson, Jennifer H.
    Jepperson, Tyler
    Willis, Scooter
    Leyland-Jones, Brian
    Dey, Nandini
    ONCOTARGET, 2017, 8 (02) : 3072 - 3103
  • [42] Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway
    Liang, Yueyang
    Wang, Shushu
    Zhang, Yi
    ONCOLOGY LETTERS, 2018, 16 (03) : 3481 - 3488
  • [43] TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1
    Pang, Yihua
    Zhao, Yanan
    Wang, Yan
    Wang, Xinlu
    Wang, Ruiqing
    Liu, Na
    Li, Peng
    Ji, Min
    Ye, Jingjing
    Sun, Tao
    Li, Jingxin
    Ma, Daoxin
    Lu, Fei
    Ji, Chunyan
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [44] TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1
    Yihua Pang
    Yanan Zhao
    Yan Wang
    Xinlu Wang
    Ruiqing Wang
    Na Liu
    Peng Li
    Min Ji
    Jingjing Ye
    Tao Sun
    Jingxin Li
    Daoxin Ma
    Fei Lu
    Chunyan Ji
    Journal of Experimental & Clinical Cancer Research, 39
  • [45] Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway
    Zhang, Yuzhu
    Chen, Jing
    Mi, Dazhao
    Ling, Jun
    Li, Huachao
    He, Peng
    Liu, Ning
    Chen, Qianjun
    Chen, Yihua
    Huang, Luqi
    CANCER LETTERS, 2023, 560
  • [46] TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition
    Zhou, Bin
    Zhan, Hanxiang
    Tin, Lamtin
    Liu, Shanglong
    Xu, Jianwei
    Dong, Yanan
    Li, Xiaoyu
    Wu, Liqun
    Guo, Weidong
    CANCER LETTERS, 2016, 382 (01) : 11 - 20
  • [47] GAPVD1 Promotes the Proliferation of Triple-negative Breast Cancer Cells by Regulating the ERK/MAPK Signaling Pathway
    Wang, Lu
    Zhang, Lifen
    Luo, Pei
    Xia, Zeyu
    Shao, Shan
    Ning, Qian
    Gu, Shanzhi
    Zhao, Xinhan
    Luo, Minna
    CURRENT CANCER DRUG TARGETS, 2025, 25 (05) : 509 - 519
  • [48] HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1
    Jiao, Dechuang
    Zhang, Jingyang
    Chen, Ping
    Guo, Xuhui
    Qiao, Jianghua
    Zhu, Jiujun
    Wang, Lina
    Lu, Zhenduo
    Liu, Zhenzhen
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (01) : 397 - 410
  • [49] Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer sternness and metastasis by inhibiting the Src/Vav2/Rac1 pathway
    Xiao, Yajuan
    Li, Yunfei
    Tao, Hua
    Humphries, Brock
    Li, Aimin
    Jiang, Yiguo
    Yang, Chengfeng
    Luo, Rongcheng
    Wang, Zhishan
    CANCER LETTERS, 2018, 433 : 199 - 209
  • [50] Plastin 1 drives metastasis of colorectal cancer through the IQGAP1/Rac1/ERK pathway
    Zhang, Tongtong
    Wang, Zheng
    Liu, Yanjun
    Huo, Yongxu
    Liu, Hongtao
    Xu, Chenxin
    Mao, Rui
    Zhu, Yifang
    Liu, Lei
    Wei, Danfeng
    Liu, Guanzhi
    Pan, Biran
    Tang, Yan
    Zhou, Zheng
    Yang, Chunlei
    Guo, Yuanbiao
    CANCER SCIENCE, 2020, 111 (08) : 2861 - 2871